Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 2/2018

Open Access 01-02-2018 | Correction

Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men

Authors: Richard Markus, Vincent Chow, Zhiying Pan, Vladimir Hanes

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2018

Login to get access

Excerpt

The article [A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men], written by [Richard Markus, Vincent Chow, Zhiying Pan and Vladimir Hanes], was originally published Online First without open access. After publication in volume [80], issue [4], page [755–763] the author decided to opt for Open Choice and to make the article an open access publication. Therefore, the copyright of the article has been changed to © The Author(s) [2017] and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The original article was corrected. …
Metadata
Title
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
Authors
Richard Markus
Vincent Chow
Zhiying Pan
Vladimir Hanes
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-017-3457-8

Other articles of this Issue 2/2018

Cancer Chemotherapy and Pharmacology 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine